Skip to main content
SpringerLink
Log in

Recombinant human erythropoietin (rhEPO) in anemia associated with multiple myeloma and non-Hodgkin’s lymphoma

  • Chapter
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology

Abstract

Anemia is observed in most patients with multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and may already be manifested at the time of diagnosis. In patients with MM, hemoglobin values <10.0g/dL were found in 49% and severe anemia (hemoglobin <7.5 g/dL) in 19% of the patients already at the time of diagnosis (MRC working party 1980). Patients with NHL have been reported to have an anemia rate of approximately 40% (Coiffier 1999). Anemia usually (but not always, especially in MM) normalizes in patients who achieve complete remission after chemotherapy. However, it persists in patients who are unresponsive to treatment, and recurs in those with relapsing disease. Anemia is a general finding in later phases of the disease, when toxicity of long-term treatment, impairment of renal function, and heavy tumor load contribute to its induction and aggravation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Barlogie B, Beck T (1993) Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 11: 88–94

    Article  PubMed  CAS  Google Scholar 

  • Beguin Y, Lampertz S, Bron D, Fillet G (1995) Serum erythropoietin in chronic lymphocyic leukaemia. Br J Haematol 93: 154–156

    Article  Google Scholar 

  • Beguin Y, Yerna M, Loo M, Weber M, Fillet G (1992) Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82: 648–653

    Article  PubMed  CAS  Google Scholar 

  • Bessho M, Hirashima K, Tsuchiya J (1994) Improvement of anemia in patients with multiple myeloma by recombinant erythropoietin: A multicenter study. Exp Hematol 22: 705 (abstract)

    Google Scholar 

  • Cazzola M, Mercuriali F, Grugnara C (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 89: 4248–4267

    PubMed  CAS  Google Scholar 

  • Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G et al (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: Dose finding and identification of predictors of response. Blood 86: 4446–4453

    PubMed  CAS  Google Scholar 

  • Cella D (1997) The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (Suppl 2): 13–19

    PubMed  CAS  Google Scholar 

  • Coiffier B (1999) Anemia associated with non-platinum chemotherapy (CT) for Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL). Eur J Cancer 35 (Suppl 4): s331 (abstract)

    Article  Google Scholar 

  • Crémieux PY, Barrett B, Anderson K, Slavin MB (2000) Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 18: 2755–2761

    PubMed  Google Scholar 

  • Dammacco F, Castoldi G, Rödjer S et al (1997) A placebo-controlled study on the effect of epoetin alpha in patients with multiple myeloma. Blood 90 (Suppl 1): 358a

    Google Scholar 

  • Denton TA, Diamond GA, Matloff JM, Gray GA (1994) Anemia therapy; individual benefit and societal cost. Semin Oncol 21 (2, Suppl 3): 29–35

    PubMed  CAS  Google Scholar 

  • Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H (1990) Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 44: 186–189

    Article  PubMed  CAS  Google Scholar 

  • Faquin WC, Schneider TJ, Goldberg MA (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79: 1987–1994

    PubMed  CAS  Google Scholar 

  • Finch CA, Huebers HA (1982) Perspectives in iron metabolism. N Engl J Med 306: 1520–1528

    Article  PubMed  CAS  Google Scholar 

  • Garton JP, Gerz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155: 2069–2074

    Article  PubMed  CAS  Google Scholar 

  • George CD, Morella PJ (1986) Immunologic effects of blood transfusion upon renal transplantation, tumor operations, and bacterial infections. Am J Surg 152: 329–337

    Article  PubMed  CAS  Google Scholar 

  • Glaspy J (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 13: 461–473

    PubMed  CAS  Google Scholar 

  • Heiss MM, Mempel W, Jauch KW, Delanoff C, Mayer G, Mampel M, Eissner HJ, Schildberg FW (1993) Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 342: 1328–1333

    Article  PubMed  CAS  Google Scholar 

  • Henry D, Glaspy J (1997) Predicting response to epoetin alfa in anemic cancer patients receiving chemorx. Proc Am Soc Clin Oncol 16: 49a (abstract)

    Google Scholar 

  • Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693–1699

    Article  PubMed  CAS  Google Scholar 

  • Ludwig H, Leitgeb C, Fritz E, Krainer M, Kuhrer I, Kornek G, Sagaster P, Weissmann A (1993) Erythropoietin treatment of chronic anemia of cancer. Eur J Cancer 29A (Suppl 2): 8–12

    Article  Google Scholar 

  • Maxwell MB (1984) When the cancer patient becomes anemic. Cancer Nurs 7: 321–326

    Article  PubMed  CAS  Google Scholar 

  • Means RT, Krantz SB (1991) Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 78: 2564–2567

    PubMed  CAS  Google Scholar 

  • Means RT (1995) Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 13: 32–37

    Article  PubMed  Google Scholar 

  • Medical Research Council’s Working Party on Leukaemia in Adults (1980) Prognostic features in the third MRC myelomatosis trial. Medical Research Council’s Working Party on Leukaemia in Adults. Br J Cancer 42: 831–840

    Article  Google Scholar 

  • Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A (1997) Recombinant human erythropoietin in the treatment of multiple myelomaassociated anemia. Acta Haematol 98: 204–210

    Article  PubMed  CAS  Google Scholar 

  • Musto P, Falcone A, D’Arena G, Scalzulli PR, Matera R, Minervini MM, Lombardi GF, Modoni S, Longo A, Carotenuto M (1997) Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis. Eur J Haematol 58: 314–319

    Article  PubMed  CAS  Google Scholar 

  • Musto P (1998) The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma. Leuk Lymphoma 29: 283–291

    Article  PubMed  CAS  Google Scholar 

  • Oster W, Herrman F, Gamm H, Zeile G, Lindemann A, Muller G, Brune T, Kraemer HP, Mertelsmann R (1990) Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8: 956–962

    PubMed  CAS  Google Scholar 

  • Pangalis GA, Poziopoulos C, Angelopoulou MK, Siakantaris MP, Panayiotidis P (1995) Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 89: 627–629

    Article  PubMed  CAS  Google Scholar 

  • Rose E, Rai K, Revicki D, Brown R, Reblando J (1994) Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 84 (Suppl 1): 526a

    Google Scholar 

  • Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70: 313–318

    Article  PubMed  CAS  Google Scholar 

  • Singh A, Eckardt KU, Zimmermann A, Gotz KH, Hamann M, Ratcliffe PJ, Kurtz A, Reinhart WH (1993) Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 91: 251–256

    Article  PubMed  CAS  Google Scholar 

  • Stockman JA III (1996) Anemia of prematurity. Current concepts in the issue of when to transfuse. Pediatr Clin North Am 33: 111–128

    Google Scholar 

  • Thomas ML (1998) Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Medical Oncology 15 (Suppl 3): 13–18

    Google Scholar 

  • Österborg A, Boogaerts M, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma-A randomized multicenter study. Blood 87: 2675–2682

    PubMed  Google Scholar 

  • Österborg A (1998) Recombinant human erythropoietin s(rHuEPO) therapy in patients with cancer-related anaemia: What have we learned? Med Oncol 15 (Suppl 1): 47–49

    Google Scholar 

  • Österborg A, Brandberg Y, Molostova V, Iosova V, Abdulkadyrov K, Hedenus M, Messinger D (2002) Randomized, double-blind, placebo-controlled trial of the effect of epoetin beta on quality of life of patients with hematological malignancies. J Clin Oncol 20: in press

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology (Radiumhemmet), Karolinska Hospital, SE-171 76, Stockholm, Sweden

    Anders Österborg

Authors
  1. Anders Österborg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anders Österborg .

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum, Essen, Universitätsklinikum, Essen, Deutschland

    M. R. Nowrousian

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag/Wien

About this chapter

Cite this chapter

Österborg, A. (2002). Recombinant human erythropoietin (rhEPO) in anemia associated with multiple myeloma and non-Hodgkin’s lymphoma. In: Nowrousian, M.R. (eds) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7658-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-7658-0_12

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7660-3

  • Online ISBN: 978-3-7091-7658-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation